Mid-term results of patterned laser trabeculoplasty for uncontrolled ocular hypertension and primary open angle glaucoma.

AIM: To describe the safety and efficacy of patterned laser trabeculoplasty (PLT) as an adjunctive treatment in primary open angle glaucoma (POAG) and ocular hypertension (OHT) after 18-month follow-up in Hispanic population. METHODS: A single-center, retrospective study was conducted. All patients with OHT or POAG undergoing PLT from June 2016 to August 2016 were included in the study. Investigated parameters were intraocular pressure (IOP), the number of IOP-lowering medications, best corrected visual acuity (BCVA), laser parameters and postoperative adverse events. Primary efficacy outcome measures were the proportion of eyes achieving an IOP reduction ≥20% at 18mo versus baseline medicated IOP or a reduction in the number of medications while maintaining IOP values. RESULTS: From 40 PLT-treated eyes (mean baseline IOP 20.3±1.7 mm Hg), 24 patients were analyzed (age 63.4±7.3y). The mean IOP reductions from baseline across visits (months 1, 3, 6, 9, 12, and 18) ranged from 14.1% to 20.8%. Success rate after 18-month follow-up was 61.7% with a mean IOP of 16±3.2 mm Hg (P<0.001). The number of glaucoma IOP-lowering medications per eye (preoperative 2.1±1.1 and postoperative 2.3±1.1, P=0.86) and the mean BCVA (preoperative 0.10±0.22 and postoperative 0.11±0.22 logMAR, P=0.42) remained stable. Adverse events comprised transitory IOP spikes in 4 eyes (10%) and peripheral anterior synechiae in 7 eyes (17.5%). CONCLUSION: Mid-term results of PLT show that this procedure may be an efficacious and safe technique to approach medically uncontrolled OHT or POAG patients.

Resultados polisomnográficos de pacientes adultos con parálisis de cuerdas vocales y diagnóstico de síndrome de apnea hipopnea obstructiva del sueño llevados a cordectomía posterior: estudio antes-después / Polisomnographic results of adult patients with bilateral vocal cord paralysis and diagnosis of hypopnea sleep apnea syndrome managed with posterior cordectomy: study before-after

Introducción: la parálisis bilateral de cuerdas vocales (PBCV) y el síndrome de apnea hipoapnea obstructiva del sueño (SAHOS) son patologías que generan limitación respiratoria. Por tratarse de patologías obstructivas, es razonable considerar una posible relación. Materiales y métodos: se realizó un estudio antes y después en dos centros universitarios de Bogotá. Se describieron frecuencias y medidas de tendencia central. Se utilizaron las pruebas de McNemar BoWker y T pareada o Wilcoxon, considerándose significativo un p <0,05. Resultados: se incluyeron 14 pacientes con PBCV manejados con cordectomía posterior transversa. 100 % fueron del género femenino y la media de edad de 51,2±10,73 años. El promedio de índice de masa corporal (IMC) fue 25,42±5,4, 50 % tuvieron IMC normal. La severidad del SAHOS fue leve (42,9 %), moderada (28,6 %) y severa (28,6 %). La intervención fue exitosa en un 64,28 %, lo que evidencia una reducción del 54 % del índice apnea/hipopnea (IAH) prequirúrgico comparado con el posquirúrgico (p = 0,029), 85,6 % reducción en el índice de apneas obstructivas (p = 0,017), en el índice de hipopneas en 52 % (p = 0,028) y la latencia del sueño en 33,3 % (p = 0,025). Otras variables no mostraron diferencias significativas (p >0,05). Conclusiones e importancia clínica: los resultados descritos evidencian una relación estadísticamente significativa del SAHOS y la PBCV. Los pacientes con PBCV se beneficiaron del uso de la cordectomía posterior como intervención terapéutica ya que disminuye los índices de severidad del SAHOS y, por ende, mejora la calidad de vida de los pacientes.

Background: bilateral vocal cord paralysis (BVFP) and obstructive sleep apnea-hypopnea syndrome (OSAHS) are pathologies that generate respiratory limitation. As they are obstructive airway diseases, it is reasonable to consider a possible relationship. Materials and methods: a before and after study was performed, in two university centers in Bogotá, frequencies and measures of central tendency were described. The McNemar BoWker and paired T or Wilcoxon tests were used, considering p <0.05 significant. Results: 14 patients were managed with transverse posterior cordectomy. 100 % were female and the mean age of 51.2±10.73 years. The average BMI was 25.42±5.4, 50 % had normal BMI. OSAHS severity was mild 42.9 %, moderate 28.6 % and severe 28.6 % disease classification. The intervention was successful in 64.28 %, there was a 54 % reduction in presurgical Apnea Hypopnea Index compared to the post-surgical one (p = 0.029), 85.6 % reduction in the index of obstructive apneas (p = 0.017), in the index of hypopneas in 52 % (p = 0.028) and sleep latency in 33.3 % (p = 0.025). Other variables showed no significant differences (p >0.05). Conclusions: the results described show a statistically significant relationship between OSAHS and BVFP. Patients with BVFP benefited from the use of posterior cordectomy as a therapeutic intervention reducing the severity rates of OSAHS and thus improving the quality of life of patients.

Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucoma and ocular hypertension.

AIM: To assess the efficacy and safety of patterned laser trabeculoplasty (PLT) as an adjunctive treatment in open angle glaucoma (OAG) or ocular hypertension (OHT) patients who were under antiglaucoma medical treatment. METHODS: This study was a retrospective review of primary or secondary OAG patients and OHT patients with medically uncontrolled (≥18 mm Hg) intraocular pressure (IOP) who underwent 360° PLT from June 2016 to August 2016. Follow-up visits at week 1, and 1, 3 and 6mo were performed. IOP, best corrected visual acuity (BCVA), complications and eye drop glaucoma medication were recorded at each follow-up visit. Success was defined as IOP reduction ≥20% from baseline. RESULTS: Forty-one eyes of 25 patients were included in this study. Pre-treatment mean IOP was 20.2±1.6 mm Hg. After PLT, IOP was 19.3±5.2, 16.1±2.7, 17.1±3.7 and 16.3±3.5 mm Hg, at 1wk, 1, 3 and 6mo, respectively. IOP reduction from baseline was statistically significant from the first month, remaining stable at 6mo (P<0.001). PLT success at 6mo of follow-up was 48.78%. The number of glaucoma medication per eye (P=0.10) and the mean BCVA both remained constant (P=0.37). Complications included transient IOP spikes in 4 eyes (9.8%) and peripheral anterior synechiae in 7 eyes (17.1%). CONCLUSION: PLT is an effective and safe method for the management of patients with OHT or OAG as an adjunctive therapy. Additional larger studies should be designed to verify the long-term stability of IOP reduction with this laser technology.

A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure.

OBJECTIVE: To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC) in primary open-angle glaucoma and ocular hypertension. METHODS: Patients with intraocular pressure (IOP) ≥23 and ≤34 mmHg were randomized to twice-daily TFC or DFC. The primary variable is the change in worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population). Secondary endpoints are mean IOP and mean change from baseline at weeks 1, 2, 4, 8, and 12 (mITT population). TFC superiority was demonstrated if the primary variable favored TFC (p ≤ 0.05). Sensitivity analyses were conducted, and safety was assessed at all visits. RESULTS: TFC (n = 93) provided greater IOP reductions from baseline than DFC (n = 97) at week 12 (treatment difference, 0.85 mmHg; p = 0.028) and all other visits. TFC was also superior to DFC in patients with high baseline IOP (i.e., IOP ≥ 25 mmHg; p ≤ 0.011). Conjunctival hyperemia, ocular irritation, and dry eye were reported more often with TFC (p ≤ 0.016); however, discontinuations for ocular adverse events were similar between treatments. CONCLUSIONS: TFC demonstrated IOP-lowering benefits that outweigh the risk of predominantly mild ocular side effects, which may be particularly relevant in patients who require greater IOP lowering to prevent/delay disease progression. This trial is registered with ClinicalTrials.gov registry number: NCT01241240.